DOCSLIB.ORG

Chapter 5: Preexisting Diabetes and Pregnancy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chapter 5: Preexisting Diabetes and Pregnancy CHAPTER 5 PREEXISTING DIABETES AND PREGNANCY John L. Kitzmiller, MD, MS, Assiamira Ferrara MD, PhD, Tiffany Peng, MA, Michelle A. Cissell, PhD, and Catherine Kim, MD, MPH Dr. John L. Kitzmiller retired in 2015 as Consultant in Maternal-Fetal Medicine and Director of the Diabetes and Pregnancy Program at Santa Clara County Medical and Health Centers, San Jose, CA, and previously as Professor of Obstetrics at UCSF, San Francisco, CA. Dr. Assiamira Ferrara is Associate Director of Women’s and Children’s Health, Division of Research, Kaiser Permanente Northern California, Oakland, CA. Ms. Tiffany Peng is Senior Data Consultant, Division of Research, Kaiser Permanente Northern California, Oakland, CA. Dr. Michelle A. Cissell is a science writer and editor, Chicago, IL. Dr. Catherine Kim is Associate Professor of Medicine, Obstetrics & Gynecology, and Epidemiology at the University of Michigan, Ann Arbor, MI. SUMMARY The prevalence of diabetes in adolescents and women of reproductive age has increased since 1995. However, no prospective national population-based data from the United States are available regarding women with preexisting diabetes in pregnancy (pregestational)— that is, type 1 diabetes or type 2 diabetes identified before pregnancy. Knowledge of the true prevalence depends on inclusion of women with early pregnancy losses, which are not available in birth certificate or hospital discharge data. In this chapter, prevalence data are presented from selected populations, including women who have recently given birth to a live infant, women who have used diabetes medications during pregnancy, women who have delivered in hospitals, and women enrolled in specific health plans. These reports, as well as population-based reports from other countries, suggest that diabetes during pregnancy has at least doubled since 1995, with increases in pregnancies affected by type 1 and type 2 diabetes and across all age groups. Surveys of diabetes in female youth show that the prevalence of type 1 diabetes is greater than type 2 diabetes, but by the time in life of pregnancy, the ratio has reversed in population-based analyses of births. The former crude prevalence of preexisting diabetes mellitus in pregnancy of approximately 0.3% has risen to 1.0%–1.9% in major parts of North America, paralleling the diabetes prevalence in repro- ductive-age women, which was approximately 1.85%–3.0% between 2002 and 2009. Preconception care of diabetes has consistently been reported to reduce major congenital malformations and perinatal complications by over 60%, thus rendering such care cost-effective. Utilization of preconception care is suboptimal, in part because of the high frequency of unplanned pregnancy, as well as lack of access to care. No national or regional surveillance systems are in place to prospectively monitor utilization of preconception care of diabetes and outcomes in the United States. Even though the risks of unplanned pregnancy are greater in women with diabetes than in nondiabetic women, women with diabetes are less likely to receive contraception counseling than women without diabetes. Large prospective studies of diabetic women from the preconception period forward are needed in order to obtain reliable data on the prevalence of preconception care of diabetes and the use of contraception, as well as the number of diabetic women becoming and remaining pregnant. This effort might also have the effect of better linkage of general diabetes care to enhanced preconception manage- ment of diabetic women. Severe maternal complications of pregnancy may be rare in the United States, but diabetes increases the relative risks of maternal mortality, ischemic stroke, myocardial infarction, preeclampsia-eclampsia, and possibly sepsis and venous thromboembolism. Prevention of diabetic ketoacidosis and severe maternal hypoglycemia is crucial; their frequencies should be monitored as indicators of quality of care, including self-care by the patient. Population-based systems to monitor these important comorbidities are lacking in the United States. Proliferative retinopathy can progress during pregnancy, but risk of vision loss can be reduced by comprehensive ophthalmologic screening and photocoagulation as necessary. Data from other countries suggest that pregnancy does not exacerbate mild nephropathy in the long term, although the presence of nephropathy can contribute to poorer birth outcomes and worsen prognosis over the long term. Hypertensive disorders affect >10% of diabetic pregnancies, contributing to neonatal morbidity. Prospective data on treatment of hypertension during diabetic pregnancy are lacking. First trimester glycosylated hemoglobin (A1c) levels >7.0% are associated with poorer birth outcomes. The teratogenic effects of hyper- glycemia may be compounded by obesity, smoking, alcohol use, and/or poor nutrition. Fetal complications include a higher frequency of major congenital malformations, the most common of which are cardiovascular. It is controversial whether the use of medications Received in final form January 24, 2018. 5–1 DIABETES IN AMERICA, 3rd Edition common among women with diabetes contributes to the malformation risk, although insulin, antihyperglycemic medications, and oral contraceptives do not appear to do so. Stillbirths occur more frequently among women with poorer glucose control, and degree of risk increases with degree of A1c elevation. The prevalences of major malformations and stillbirths in surveys depend on the inclusion of terminations of pregnancy or late fetal losses at 20–23 weeks gestation, respectively. Women with diabetes also have a 30%–60% higher risk of infants affected by preterm delivery and macrosomia with concomitant birth trauma events, such as shoulder dystocia with vaginal delivery. In 2009, approximately 56.5% of births to women with pregestational diabetes mellitus were by cesarean section, and 16%–27% of births resulted in birth weights >4,000 g. Other adverse events among infants of mothers with diabetes include infant mortality and neonatal hypoxic-ischemic encephalopathy, although such events are infre- quent. Infants of diabetic mothers can experience a higher frequency of respiratory distress, polycythemia, hypoglycemia, hypocalcemia, and hyperbilirubinemia compared to infants of mothers without diabetes. In rare cases, these complications also can contribute to neonatal encephalopathy. The increasing frequency of type 1 and type 2 diabetes in young women and increasing maternal age at conception are likely to further increase the risk of adverse maternal, birth, and infant outcomes. Population-based data are needed to track conception, miscarriage, major malformations, and livebirth and stillbirth frequencies among women with diabetes. Such data would guide the optimal timing and tailoring of preconception interventions. Interventions are needed that quantify the optimal amount of surveillance during fetal develop- ment (balancing costs and benefits), along with interventions that examine long-term risk to mothers and offspring. The subject matter in this chapter is necessarily broad, as it not only discusses prevalence of pregestational diabetes mellitus in preg- nancy but also prevalence of diabetes in reproductive-age women; preconception care and contraception; complications in the mother, fetus, infant, and developing offspring; and methodologic issues related to assessment of outcomes in the mother, fetus, and infant. The beauty and the devil is in the details. The definitions and management of pregnancy-related conditions can vary considerably among studies and, in many cases, are controversial. INTRODUCTION OBJECTIVE HISTORICAL CONTEXT obesity and type 2 diabetes. The latter is This chapter presents population-based or Prior to the application of (a) medical too often unrecognized until pregnancy multicenter data on: (1) the growing preva- nutrition therapy, self-monitoring of is well established. Regional or national lence of type 1 and type 2 diabetes before maternal blood glucose, and individualized surveillance of diabetes and pregnancy and during pregnancy in North America, insulin regimens, (b) technologies of fetal outcomes at the community level in the (2) preconception care and contraception assessment, and (c) intensive neonatal United States has not kept pace with among those with diabetes, (3) maternal care, pregnancy in women with type 1 achievements at centers of excellence. complications of preexisting diabetes in diabetes (then defined as child-onset, These problems gain even more impor- pregnancy, and (4) fetal, neonatal, and insulin-dependent) was a frightening affair tance with the recognition of the lifelong offspring outcomes among women with (1). Maternal risks included diabetic keto- influences of preconception, fetal, and diabetes. Information on diabetes with acidosis (DKA), hypoglycemic coma, and neonatal processes on many features of onset or recognition during pregnancy is progression of vascular disease, including health or disease. provided in Chapter 4 Gestational Diabetes. superimposed preeclampsia. Excess rates This chapter focuses on data published in of early fetal loss, major congenital malfor- In the 1980s–1990s, two national peer-reviewed journals since 2000. If ample mations, fetal growth restriction, stillbirth, prospective studies included a focus U.S. data are not available on the different birth trauma, and neonatal death from on type 1 diabetes and pregnancy. The topics, relevant international popula- hyaline membrane
Load more

Recommended publications
  • The Diagnostic Impact of Limited, Screening Obstetric Ultrasound When Performed by Midwives in Rural Uganda
    Journal of Perinatology (2014) 34, 508–512 © 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE The diagnostic impact of limited, screening obstetric ultrasound when performed by midwives in rural Uganda JO Swanson1, MG Kawooya2, DL Swanson1, DS Hippe1, P Dungu-Matovu2 and R Nathan1 OBJECTIVE: To evaluate the diagnostic impact of limited obstetric ultrasound (US) in identifying high-risk pregnancies when used as a screening tool by midwives in rural Uganda. STUDY DESIGN: This was an institutional review board-approved prospective study of expecting mothers in rural Uganda who underwent clinical and US exams as part of their standard antenatal care visit in a local health center in the Isingiro district of Uganda. The midwives documented clinical impressions before performing a limited obstetric US on the same patient. The clinical findings were then compared with the subsequent US findings to determine the diagnostic impact. The midwives were US-naive before participating in the 6-week training course for limited obstetric US. RESULT: Midwife-performed screening obstetric US altered the clinical diagnosis in up to 12% clinical encounters. This diagnostic impact is less (6.7 to 7.4%) if the early third trimester diagnosis of malpresentation is excluded. The quality assurance review of midwives’ imaging demonstrated 100% sensitivity and specificity in the diagnosing gestational number, and 90% sensitivity and 96% specificity in the diagnosis of fetal presentation. CONCLUSION: Limited, screening obstetric US performed by midwives with focused, obstetric US training demonstrates the diagnostic impact for identifying conditions associated with high-risk pregnancies in 6.7 to 12% of patients screened.
    [Show full text]
  • Type 1 Diabetes and Pregnancy
    Type 1 diabetes and pregnancy Information for patients 1 2 Contents How will diabetes affect my pregnancy? 4 How will diabetes affect my baby? 5 My antenatal care 6 Hypoglycaemia 9 Planning for your birth 12 After your baby is born 15 Nutrition and related issues 17 Diet and lifestyle Controlling your blood glucose levels with diet Fluid intake Fat in foods Calcium Iron Folic acid and diabetes Diabetic products Symptoms in pregnancy How much weight should I expect to put on? Physical activity Suitable snacks Additional information Breastfeeding and diabetes 31 What happens once my baby is born? 34 For the future 37 References and useful links 39 3 This booklet aims to tell you what care to expect during and after your pregnancy when you have diabetes. It will not answer every question you may have, so please write any concerns down and ask your midwife or doctor. We run a joint antenatal and diabetes clinic at Barnet Hospital and the Royal Free Hospital. We have a dedicated multidisciplinary team who will review you on a regular basis to provide advice and support throughout your pregnancy. The team consists of a consultant endocrinologist, obstetrician, diabetes specialist midwife, diabetes specialist nurse and a diabetes specialist dietitian. How will diabetes affect my pregnancy? With good pre-conception care and good diabetes control there is every chance of a successful pregnancy. As soon as your pregnancy is confirmed, you should attend the joint diabetes antenatal clinic. Here you will receive support and advice to enable you to obtain and maintain good control of your diabetes as early in your pregnancy as possible.
    [Show full text]
  • Breech Presentation at Delivery: a Marker for Congenital Anomaly?
    Journal of Perinatology (2014) 34, 11–15 & 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE Breech presentation at delivery: a marker for congenital anomaly? D Mostello1, JJ Chang2, F Bai2, J Wang3, C Guild4, K Stamps2 and TL Leet2,{ OBJECTIVE: To determine whether congenital anomalies are associated with breech presentation at the time of birth. STUDY DESIGN: A population-based, retrospective cohort study was conducted among 460 147 women with singleton live births using the Missouri Birth Defects Registry, which includes all defects diagnosed during the first year of life. Maternal and obstetric characteristics and outcomes between breech and cephalic presentation groups were compared using w2-square statistic and Student’s t-test. Multivariable binary logistic regression analysis was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). RESULT: At least one congenital anomaly was more likely present among infants breech at birth (11.7%) than in those with cephalic presentation (5.1%), whether full-term (9.4 vs 4.6%) or preterm (20.1 vs 11.6%). The relationship between breech presentation and congenital anomaly was stronger among full-term births (aOR 2.09, CI 1.96, 2.23, term vs 1.40, CI 1.26, 1.55, preterm), but not in all categories of anomalies. CONCLUSION: Breech presentation at delivery is a marker for the presence of congenital anomaly. Infants delivered breech deserve special scrutiny for the presence of malformation. Journal of Perinatology (2014) 34, 11–15;
    [Show full text]
  • A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
    ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction ..............................................................................................................
    [Show full text]
  • Twin Pregnancy with Triploidy and Co-Existing Live Twin Progressing to Viability: Case Study and Literature Review
    Obstetrics & Gynecology International Journal Case Report Open Access Twin pregnancy with triploidy and co-existing live twin progressing to viability: Case study and literature review Abstract Volume 9 Issue 4 - 2018 Background: Twin pregnancies consisting of a triploid fetus with molar change and a 1,2 1,2 1,2 healthy coexisting fetus is an extremely rare phenomenon. Triploidy rarely advances to the Cingiloglu P, Yeung T, Sekar R second trimester, most resulting in a miscarriage, termination or stillbirth. Only five cases 1Royal Brisbane and Women’s Hospital, Women’s and Newborn of a triploid fetus and a healthy co-twin have been reported in literature. We present the first Services, Australia documented case of a live delivery of both triploid fetus and coexisting viable twin. 2University of Queensland, Australia Case presentation: A 23-year old woman, gravida 2, para 1 was admitted at 26+4 weeks Correspondence: Pinar Cingiloglu, Women’s and Newborn gestation with DCDA twins and a shortened cervix. Sonography revealed polyhydramnios, Services, Royal Brisbane and Women’s Hospital, Bowen Bridge an abnormal cystic placenta, and small aortic valve for the presenting twin. Emergency Road&, Butterfield St, Herston Queensland Australia, Tel +61 caesarean section was performed at 28 weeks gestation for cord prolapse. Twin A was born (07) 3646 8111, Email [email protected] a live infant with ambiguous genitalia, syndactyly, epicanthic folds and cerebral cysts. Twin B was born a healthy live male. Histopathology revealed features consistent with Received: June 13, 2018 | Published: July 13, 2018 partial hydatidiform mole, and cytogenetics revealed a diandric triploidy in twin A.
    [Show full text]
  • Diabetes and Planning for Pregnancy
    Form: D-5227 Diabetes and Planning for Pregnancy Information for women with diabetes and their families Read this booklet to learn about: • planning for pregnancy when you have diabetes • how your health care team can help • managing your blood sugar Why do I need to plan for my pregnancy if I have diabetes? Getting pregnant and having a healthy baby can be a very exciting time in your life. If you have diabetes, it’s very important to plan ahead so you are as healthy as possible and your pregnancy is safe. Not controlling your blood sugar levels before and during pregnancy can cause health problems for you and your baby: • High blood sugars during the first 3 months of your pregnancy can cause your baby to have problems developing and you to miscarry. • High blood sugars during your pregnancy can cause your baby to grow too large. This can be a health risk for you and your baby. • The changes that happen in your body during pregnancy can cause any problems you already have because of diabetes to become worse. Work together with your health care team so you can have the healthiest and safest pregnancy possible. Talk to them about birth control so you can prevent pregnancy until your blood sugars are controlled. Who are members of my health care team? Before getting pregnant, your health care team may include a: • diabetes nurse educator • dietitian • endocrinologist • obstetrician/gynecologist • family doctor • ophthalmologist • nephrologist • cardiologist 2 We may refer you to a team that specializes in diabetes and pregnancy. How do I prepare for pregnancy? 9 Tell your health care team you are planning to get pregnant at least 3 months before you start trying.
    [Show full text]
  • Gtg-No-20B-Breech-Presentation.Pdf
    Guideline No. 20b December 2006 THE MANAGEMENT OF BREECH PRESENTATION This is the third edition of the guideline originally published in 1999 and revised in 2001 under the same title. 1. Purpose and scope The aim of this guideline is to provide up-to-date information on methods of delivery for women with breech presentation. The scope is confined to decision making regarding the route of delivery and choice of various techniques used during delivery. It does not include antenatal or postnatal care. External cephalic version is the topic of a separate RCOG Green-top Guideline No. 20a: ECV and Reducing the Incidence of Breech Presentation. 2. Background The incidence of breech presentation decreases from about 20% at 28 weeks of gestation to 3–4% at term, as most babies turn spontaneously to the cephalic presentation. This appears to be an active process whereby a normally formed and active baby adopts the position of ‘best fit’ in a normal intrauterine space. Persistent breech presentation may be associated with abnormalities of the baby, the amniotic fluid volume, the placental localisation or the uterus. It may be due to an otherwise insignificant factor such as cornual placental position or it may apparently be due to chance. There is higher perinatal mortality and morbidity with breech than cephalic presentation, due principally to prematurity, congenital malformations and birth asphyxia or trauma.1,2 Caesarean section for breech presentation has been suggested as a way of reducing the associated perinatal problems2,3 and in many countries in Northern Europe and North America caesarean section has become the normal mode of breech delivery.
    [Show full text]
  • Advising Women with Diabetes in Pregnancy to Express Breastmilk In
    Articles Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial Della A Forster, Anita M Moorhead, Susan E Jacobs, Peter G Davis, Susan P Walker, Kerri M McEgan, Gillian F Opie, Susan M Donath, Lisa Gold, Catharine McNamara, Amanda Aylward, Christine East, Rachael Ford, Lisa H Amir Summary Lancet 2017; 389: 2204–13 Background Infants of women with diabetes in pregnancy are at increased risk of hypoglycaemia, admission to a See Editorial page 2163 neonatal intensive care unit (NICU), and not being exclusively breastfed. Many clinicians encourage women with See Comment page 2167 diabetes in pregnancy to express and store breastmilk in late pregnancy, yet no evidence exists for this practice. We Judith Lumley Centre, School of aimed to determine the safety and efficacy of antenatal expressing in women with diabetes in pregnancy. Nursing and Midwifery, La Trobe University, Methods We did a multicentre, two-group, unblinded, randomised controlled trial in six hospitals in Victoria, Australia. Melbourne, VIC, Australia (Prof D A Forster PhD, We recruited women with pre-existing or gestational diabetes in a singleton pregnancy from 34 to 37 weeks’ gestation A M Moorhead RM, and randomly assigned them (1:1) to either expressing breastmilk twice per day from 36 weeks’ gestation (antenatal L H Amir PhD); Royal Women’s expressing) or standard care (usual midwifery and obstetric care, supplemented by support from a diabetes educator). Hospital, Parkville, VIC, Randomisation was done with a computerised random number generator in blocks of size two and four, and was Australia (Prof D A Forster, A M Moorhead, S E Jacobs MD, stratified by site, parity, and diabetes type.
    [Show full text]
  • 14. Management of Diabetes in Pregnancy: Standards of Medical
    Diabetes Care Volume 42, Supplement 1, January 2019 S165 14. Management of Diabetes in American Diabetes Association Pregnancy: Standards of Medical Care in Diabetesd2019 Diabetes Care 2019;42(Suppl. 1):S165–S172 | https://doi.org/10.2337/dc19-S014 14. MANAGEMENT OF DIABETES IN PREGNANCY The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. DIABETES IN PREGNANCY The prevalence of diabetes in pregnancy has been increasing in the U.S. The majority is gestational diabetes mellitus (GDM) with the remainder primarily preexisting type 1 diabetes and type 2 diabetes. The rise in GDM and type 2 diabetes in parallel with obesity both in the U.S. and worldwide is of particular concern. Both type 1 diabetes and type 2 diabetes in pregnancy confer significantly greater maternal and fetal risk than GDM, with some differences according to type of diabetes. In general, specific risks of uncontrolled diabetes in pregnancy include spontaneous abortion, fetal anomalies, preeclampsia, fetal demise, macrosomia, neonatal hypoglycemia, and neonatal hyperbilirubinemia, among others.
    [Show full text]
  • Myo-Inositol, Probiotics, and Micronutrient Supplementation
    Diabetes Care Volume 44, May 2021 1091 Myo-Inositol, Probiotics, and Keith M. Godfrey,1,2 Sheila J. Barton,1 Sarah El-Heis,1 Timothy Kenealy,3 Micronutrient Supplementation Heidi Nield,1 Philip N. Baker,4 Yap Seng Chong,5,6 Wayne Cutfield,3,7 From Preconception for Glycemia Shiao-Yng Chan,5,6 and NiPPeR Study Group* in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial Diabetes Care 2021;44:1091–1099 | https://doi.org/10.2337/dc20-2515 OBJECTIVE Better preconception metabolic and nutritional health are hypothesized to pro- mote gestational normoglycemia and reduce preterm birth, but evidence sup- 1MRC Lifecourse Epidemiology Unit, University porting improved outcomes with nutritional supplementation starting of Southampton, Southampton, U.K. CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL preconception is limited. 2NIHR Southampton Biomedical Research Centre, University Hospital Southampton, NHS RESEARCH DESIGN AND METHODS Foundation Trust, Southampton, Southampton, U.K. This double-blind randomized controlled trial recruited from the community 3Liggins Institute, University of Auckland, 1,729 U.K., Singapore, and New Zealand women aged 18–38 years planning con- Auckland, New Zealand 4 ception. We investigated whether a nutritional formulation containing myo-inosi- College of Life Sciences, Biological Sciences and Psychology, University of Leicester, tol, probiotics, and multiple micronutrients (intervention), compared with a Leicester, U.K. standard micronutrient supplement (control), taken preconception and through- 5Department of Obstetrics and Gynaecology, out pregnancy could improve pregnancy outcomes. The primary outcome was Yong Loo Lin School of Medicine, National combined fasting, 1-h, and 2-h postload glycemia (28 weeks’ gestation oral glu- University of Singapore and National University Health System, Singapore cose tolerance test).
    [Show full text]
  • Hyperglycemia and Pregnancy in the Americas
    HYPERGLYCEMIA AND PREGNANCY IN THE AMERICAS Final report of the Pan American Conference on Diabetes and Pregnancy Lima (Peru), 8-10 September 2015 HYPERGLYCEMIA AND PREGNANCY IN THE AMERICAS Final report of the Pan American Conference on Diabetes and Pregnancy Lima (Peru), 8-10 September 2015 Washington, D.C., 2016. Also published in Spanish (2016): Hiperglucemia y embarazo en las Américas: Informe final de la Conferencia Panamericana sobre Diabetes y Embarazo (Lima, Perú. 8-10 de setiembre del 2015) ISBN 978-92-75-31883-6 PAHO HQ Library Cataloguing-in-Publication Data ****************************************************************************************************** Pan American Health Organization. Hyperglycemia and Pregnancy in the Americas. Final report of the Pan American Conference on Diabetes and Pregnancy (Lima Peru: 8-10 September 2015). Washington, DC : PAHO. 2016 1. Diabetes Mellitus. 2. Hyperglycemia. 3. Pregnancy. 4. Pregnancy in Diabetics. 5. Maternal and Child Health. 6. Americas. I. Title. ISBN 978-92-75-11883-2 (NLM Classification:WQ248) © Pan American Health Organization, 2016. All rights reserved. The Pan American Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and inquiries should be addressed to the Communications Department, Pan American Health Organization, Washington, D.C., U.S.A. (www.paho.org/permissions). The Department of Noncommunicable Diseases and Mental Health will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available. Publications of the Pan American Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention.
    [Show full text]
  • Combined Analysis of Gestational Diabetes and Maternal Weight
    www.nature.com/scientificreports OPEN Combined analysis of gestational diabetes and maternal weight status from pre‑pregnancy through post‑delivery in future development of type 2 diabetes Ling‑Wei Chen1,13, Shu E Soh1,2,13, Mya‑Thway Tint1,3, See Ling Loy4,5, Fabian Yap5,6, Kok Hian Tan5,7, Yung Seng Lee1,2,8, Lynette Pei‑Chi Shek1,2,8, Keith M. Godfrey9, Peter D. Gluckman1,10, Johan G. Eriksson1,3,11,12, Yap‑Seng Chong1,3 & Shiao‑Yng Chan1,3* We examined the associations of gestational diabetes mellitus (GDM) and women’s weight status from pre‑pregnancy through post‑delivery with the risk of developing dysglycaemia [impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes (T2D)] 4–6 years post‑delivery. Using Poisson regression with confounder adjustments, we assessed associations of standard categorisations of prospectively ascertained pre‑pregnancy overweight and obesity (OWOB), gestational weight gain (GWG) and substantial post‑delivery weight retention (PDWR) with post‑delivery dysglycaemia (n = 692). Women with GDM had a higher risk of later T2D [relative risk (95% CI) 12.07 (4.55, 32.02)] and dysglycaemia [3.02 (2.19, 4.16)] compared with non‑GDM women. Independent of GDM, women with pre‑pregnancy OWOB also had a higher risk of post‑delivery dysglycaemia. Women with GDM who were OWOB pre‑pregnancy and had subsequent PDWR (≥ 5 kg) had 2.38 times (1.29, 4.41) the risk of post‑delivery dysglycaemia compared with pre‑pregnancy lean GDM women without PDWR. No consistent associations were observed between GWG and later dysglycaemia risk.
    [Show full text]